Skip to content
Browse
LatestWorldBusinessSci & TechEntertainmentSportsHealthGames

Edition

GLGlobalUSUSACACanadaUKUKINIndiaPKPakistanSGSingaporeAUAustralia

Sections

Appearance

AboutSourcesContactPrivacy

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s…

First reported by The Guardian 1 source
Image: The Guardian
Image: The Guardian
Read at The Guardian(opens in a new tab)

Full coverage

Every report we found on this story, oldest first. Each links to the original publisher.

  1. The Guardian

    Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn (opens The Guardian in a new tab)

    GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin,…

Something wrong with how we've grouped or summarised this story? Report a problem

More in World

More